Patient-derived xenograft (PDX) models are valuable surrogates for drug testing in precision oncology. In this Review, Welm and colleagues outline the opportunities and challenges of PDX models, discuss their relevance in functional precision oncology for replicating patient biology and share their perspective on how integrating these models with artificial intelligence can enhance their utility for personalizing cancer treatment.
- Zannel Blanchard
- Elisabeth A. Brown
- Alana L. Welm
